NTHI

+ Watchlist + Portfolio

NeOnc Technologies Holdings, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.63
52-Week Range: $3.01 – $12.99
Market Cap: $118.27M
P/E (TTM): —
EPS (TTM): -2.12
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -634.99%
Gross Margin: 100.00%
Operating Margin: -104418.90%
Profit Margin: 0.00%
Current Ratio: 0.18
Debt/Equity: —
Total Debt: $328.22K
Free Cash Flow: $5.40M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $114.84M

NTHI Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$20.00K	$70.46K	$83.00K	$39.99K
Research & Development	$1.16M	$1.53M	$3.05M	$3.64M
Selling, General & Admin	$1.69M	$3.40M	$3.68M	$42.85M
Operating Expenses	$2.86M	$8.17M	$7.23M	$58.21M
Operating Income	-$2.84M	-$8.10M	-$7.14M	-$58.17M
EBITDA	-$2.85M	-$12.20M	-$9.10M	-$59.61M
Pretax Income	-$3.05M	-$14.92M	-$11.90M	-$62.15M
Net Income	-$3.05M	-$14.92M	-$11.90M	-$62.15M
Diluted EPS	-0.16	-0.80	-0.63	-3.20
Diluted Shares	18.75M	18.75M	18.75M	19.40M

NTHI Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$633.30K	$31.86K	$64.89K	$58.73K
Current Assets	$728.68K	$1.27M	$2.20M	$1.39M
Total Assets	$728.68K	$1.27M	$3.42M	$2.82M
Current Liabilities	$2.30M	$15.25M	$8.92M	$20.04M
Total Debt	$50.00K	$6.61M	$24.72K	$6.31M
Total Liabilities	$2.30M	$15.25M	$8.92M	$20.33M
Retained Earnings	-$23.79M	-$38.71M	-$50.61M	-$112.75M
Shareholders' Equity	-$1.58M	-$13.99M	-$5.50M	-$17.51M
Working Capital	-$1.58M	-$13.99M	-$6.73M	-$18.65M
Net Debt	—	$6.57M	—	$5.89M

NTHI Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$881.74K	-$1.88M	-$4.21M	-$20.36M
Capital Expenditure	—	—	—	-$500.00K
Free Cash Flow	-$881.74K	-$1.88M	-$4.21M	-$20.86M
Depreciation & Amortisation	—	$0.00	$245.94K	$36.46K
Stock-Based Compensation	$1.29M	$0.00	$0.00	$35.56M
Investing Cash Flow	—	—	$0.00	-$500.00K
Financing Cash Flow	$1.49M	$1.28M	$4.25M	$20.86M
Net Change in Cash	$608.26K	-$601.44K	$33.03K	-$6.16K

NTHI Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$39.99K	$0.00	$0.00	$0.00	$0.00
Research & Development	$998.22K	$677.33K	$715.04K	$1.25M	$1.29M
Selling, General & Admin	$19.20M	$5.03M	$6.22M	$12.40M	$4.41M
Operating Expenses	$31.94M	$5.71M	$6.93M	$13.63M	$7.01M
Operating Income	-$31.90M	-$5.71M	-$6.93M	-$13.63M	-$7.01M
EBITDA	-$32.02M	-$5.61M	-$7.73M	-$14.25M	-$7.81M
Pretax Income	-$32.33M	-$5.68M	-$8.62M	-$15.52M	-$8.82M
Net Income	-$32.33M	-$5.68M	-$8.62M	-$15.52M	-$8.82M
Diluted EPS	-1.78	-0.30	-0.45	—	-0.38
Diluted Shares	18.14M	19.03M	19.21M	—	23.29M

NTHI Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$5.44M	$125.04K	$1.51M	$58.73K	$138.60K
Current Assets	$7.36M	$1.65M	$2.96M	$1.39M	$2.10M
Total Assets	$8.44M	$2.99M	$4.08M	$2.82M	$3.33M
Current Liabilities	$18.07M	$14.48M	$15.59M	$20.04M	$16.29M
Total Debt	—	$395.51K	$5.08M	$6.31M	$346.05K
Total Liabilities	$18.07M	$14.80M	$15.90M	$20.33M	$16.56M
Retained Earnings	-$88.61M	-$88.61M	-$97.23M	-$112.75M	-$121.57M
Shareholders' Equity	-$9.62M	-$11.82M	-$11.81M	-$17.51M	-$13.23M
Working Capital	-$10.71M	-$12.82M	-$12.63M	-$18.65M	-$14.19M
Net Debt	—	—	$3.19M	$5.89M	—

NTHI Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$5.65M	-$5.31M	-$5.81M	-$3.59M	-$6.99M
Free Cash Flow	-$5.65M	-$5.31M	-$5.81M	-$4.09M	-$6.99M
Depreciation & Amortisation	$0.00	$18.15K	$18.31K	$0.00	$31.98K
Stock-Based Compensation	$17.40M	$3.53M	$5.04M	$9.59M	$2.73M
Financing Cash Flow	$11.02M	$0.00	$7.20M	$2.64M	$7.07M
Net Change in Cash	$5.37M	-$5.31M	$1.39M	-$1.45M	$79.87K

Market Snapshot

About

NeOnc Technologies Holdings is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer treatment. The company is advancing neoadjuvant and adjuvant oncology programs targeting solid tumors with novel mechanisms designed to improve patient outcomes in challenging cancer indications.